The Next Generation in Metabolic Optimization: Bioglutide (aIQ-931)

At AlchemIQ Labs, we don’t just follow the science we help write it. While others speculate, we lead with rigorous research, innovative formulations, and uncompromising integrity. Our mission is simple but bold: to redefine what’s possible in cellular medicine and performance by delivering compounds that actually work, not just buzzwords. Every formula we create is grounded in peer-reviewed science. Biogoutide is a first-in-class oral therapy designed to go beyond standard GLP-1 drugs. Where current treatments often sacrifice muscle or cause harsh GI side effects, Bioglutide leverages a quadruple receptor agonist strategy, activating IGF-1, GLP-1, GIP, and glucagon receptors simultaneously.

This synergy creates a powerful metabolic reset:

GLP-1 + GIP → enhance insulin secretion, improve glucose control, and suppress appetite at the brain level.

Glucagon receptor → boosts fat oxidation and raises energy expenditure.

IGF-1 receptor → protects and preserves lean muscle mass while fat is being mobilized.

Unlike injectables, Bioglutide is orally bioavailable, and is being researched as a once-daily, and able to cross the blood–brain barrier for central appetite modulation.

Clinical Proof

In Phase 2 clinical trials (13 weeks, 125 participants):

Up to 13.8% body weight reduction at the top dose (150 mg/day).No muscle loss observed a key differentiator from GLP-1 monotherapies. Mild side effects only (nausea, diarrhea in <8%), with no severe adverse events.

These results position Bioglutide as a superior alternative to single-pathway GLP-1 drugs like semaglutide and tirzepatide, especially for those prioritizing fat loss without compromising muscle integrity.

Why It Matters

Current GLP-1 agonists are effective but blunt tools—they drive appetite suppression and weight loss but often at the expense of lean tissue and overall metabolic resilience. Bioglutide changes the game by:

Targeting multiple pathways at once for balanced, durable results.

Preserving muscle through IGF-1 activation while accelerating fat oxidation.

Enhancing compliance with a simple, oral, once-daily dose.

The Future of Obesity and Metabolic Care

Bioglutide is advancing into Phase 3 global studies for obesity, diabetes, and metabolic syndrome with potential applications in MASH (metabolic steatohepatitis) and related disorders. Early combination studies with semaglutide and tirzepatide suggest even greater impact when layered with current standards of care.

Bioglutide at a Glance

Class: Quadruple receptor agonist (IGF-1, GLP-1, GIP, Glucagon)

Format: Oral, once-daily tablet

Outcomes: 13.8% bodyweight reduction in 13 weeks, preserved muscle mass

Safety: Mild, transient GI events; no severe side effects

Status: Completed Phase 2, moving into Phase 3 trials FOR RESEARCH USE ONLY

Bioglutide delivers what the next generation of metabolic therapy demands: powerful fat loss, lean mass protection, and sustainable metabolic health without the compromises of today’s drugs.

This is your chance to be more than a spectator you can be one of just 70 researchers in the country to secure access to aIQ-931. The window is narrow, and once these slots are gone, they’re gone. If you want to stand at the leading edge of discovery, shaping the future while others are still catching up, this is the moment to move. Be first, be bold, and be part of the select few pushing science forward with AlchemIQ Labs. www.alchemIQlabs.com

47 comments